One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

NCT06618313 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Non-Hodgkin Lymphoma-Recurrent
B-Cell Non-Hodgkin Lymphoma-Refractory

Interventions

DRUG: JCXH-213,an mRNA-LNP based in vivo CAR therapy

Sponsor

Beijing GoBroad Hospital

Collaborators

[object Object]